An investigational therapy significantly shrank lung cancer tumors that are notoriously resistant to treatment by encouraging ...

New antibody AHA-1031 shows potential in treating non small cell lung cancer resistant to immunotherapy, offering new hope.

Immunotherapy is the form of treatment that redirects the immune system toward a pathogen or disease. In many cases, ...

Another antibody drug conjugate disitamab vedotin (an anti-HER2 antibody drug conjugate with MMAE payload) has also been shown to potentially pair well with immunotherapy. Disitamab vedotin + ...

The Global Cancer Immunotherapy Market achieved a valuation of $121.2 Billion in 2023 and is anticipated to exceed $245.37 ...

University of Pittsburgh School of Medicine and UPMC Hillman Cancer Center scientists have discovered a novel subset of ...

The FDA granted fast track status to IBI363 for the treatment of patients with advanced squamous lung cancer after prior ...

With the Trump administration announcing plans to impose 25% tariffs on pharmaceuticals, it reignites a critical discussion ...

AbbVie and Xilio Therapeutics have announced a partnership worth over $2.1bn to develop tumour-activated, antibody-based immunotherapies. The collaboration and option-to-licence agreement will include ...

Aditya Bardia, MD, MPH, FASCO, medical oncologist, UCLA Health, provides new insights on the role of TROP2-directed antibody drug conjugates (ADCs) for patients with breast cancer.

Scientists have discovered a novel subset of cancer-fighting immune cells that reside outside of their normal neighborhood -- known as the tertiary lymphoid structure -- where they become ...